GVR Report cover Zika Virus Testing Market Size, Share & Trends Report

Zika Virus Testing Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Amplification Testing (NAAT), Serological Testing), By Region, Vendor Landscape, And Segment Forecasts, 2018 - 2027

  • Report ID: GVR-2-68038-356-0
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2017
  • Industry: Healthcare

Industry Outlook

The global zika virus Testing market size was valued at USD 131.9 million in 2016. It is projected to exhibit a CAGR of 7.6% over the forecast period. Involvement of international organizations, such as UNICEF, and national governments in low-income developing regions is one of the key trends stimulating market growth. In addition, zika virus (ZIKV) outbreak in 2016 has helped the market gain tremendous traction.

U.S. States ZIKV Testing market

In this market, Brazil recorded the highest number of microcephaly cases, close to 1,950, from 2015 to 2016. Zika virus was declared a threat to public health in October 2016 after Brazilian authorities discovered a correlation between ZIKV infection and neurological birth defects. This recently drawn connection between microcephaly in newborns with ZIKV infection has raised surveillance efforts and the demand for diagnostics after the end of Zika epidemic in 2016. As of April 2017, CDC reported that 5,264 people were infected with Zika in the U.S., where more than 1,700 pregnant women were found Zika-positive and 58 babies were born with birth defects.

Zika epidemic in 2016 was largely a result of travel-related transmission in certain countries. In the U.S., 4,830 cases of travel-related Zika virus infections, which accounted for 94.0% of the total case counts in 2016, were reported. Hence, blood screening for Zika infection has been incorporated in addition to testing of symptomatic cases to prevent disease transmission, which is driving the demand for ZIKV diagnostics. The U.S. and Singapore markets, primarily, follow diagnostic testing of blood donations for Zika virus infections.

Organizations such as WHO, PAHO, and UNICEF initiated response strategies for Zika outbreak as the socioeconomic impact, felt globally, was severe. These strategies range from arranging diagnostics to disease treatment reserves. Apart from funding therapeutic and prophylactic research for Zika virus disease, the organizations are leaning toward stockpiling diagnostics for emergencies in the future, which is supporting the growth of the market.

Development of POC diagnostics that yield rapid results is likely to shape the future of the market. UNICEF along with PAHO is offering advanced purchasing commitments (APC) tenders to encourage production of rapid diagnostics for zika virus detection. These APCs serve ZIKV endemic regions that are at risk of witnessing future outbreaks and require rapid diagnostic tests. Chembio Diagnostics Systems, Inc. and SD Biosensors, Inc. sealed UNICEF contracts for supply of their Zika detection tests valid through 2019.

Test Type Insights

Both diagnostic test types, NAAT and serological testing, held nearly equal market shares in 2016 as during the epidemic, both tests were performed on the majority of subjects, to confirm ZIKV infection. However, the NAAT segment edged over by a small margin as it is more widely available and can be used for large scale surveillance with cost-effectiveness.

U.S. States & Territories ZIKV Testing market

With the end of epidemic in early 2017, serological diagnostics started gaining preference to NAAT as they can detect acute as well as late-stage ZIKV infection. In addition, emerging rapid detection serological diagnostics offer shorter turnaround time as well as differential diagnosis of Zika against other flaviviruses.

Regional Insights

From a geographical standpoint, the zika virus diagnostics market is classified into the U.S. States and territories, Europe, Asia Pacific, Latin America, and Africa.

In 2016, the U.S. states and territories dominated the market. Since the outbreak, the U.S. has developed a national response framework to prevent virus spread across the country by collaborating with organizations, such as the CDC, WHO, and PAHO. The country-wide mandate that was passed in 2016, requiring all donated blood to undergo individual donor-NAAT screening for Zika virus is the underlying factor contributing to the growth of the regional market.

Latin America was the second largest market in 2016 and it accounted for more than 50% of the global ZIKV infections. In addition, the presence of vector, Aedes aegypti mosquitoes, increases the chances of viral growth in this region. More than 4,000 suspected cases of microcephaly in newborns were reported in Brazil in the span of four months, from October 2015 to January 2016. Availability of funding worth USD 136.6 million from Brazil’s National Development Bank (BNDES), announced in March 2016, to fight vector-borne illnesses including ZIKV is also working in favor of the regional market.

Zika Virus Testing Market Share Insights

Competition among the market players is high. During Zika epidemic in 2016, Roche; Quest Diagnostics, Inc.; and Hologic, Inc. were the leading market players with FDA-EUA approved products.

End of the epidemic phase led to changes in the competitive landscape of the market.

In early 2017, companies, including Chembio Diagnostic Systems, Inc.; SD Biosensors, Inc.; and Biocan Diagnostics introduced improved diagnostics. With the recent contract received from UNICEF worth USD 10.5 million, Chembio Diagnostics, Inc. is expected to be the leading market player over the forecast period.

Report Scope



Base year for estimation


Actual estimates/Historical data

2016 - 2017

Forecast period

2017 - 2027

Market representation

Revenue in USD Million & CAGR from 2017 to 2027

Regional scope



U.S. States & Territories, Europe, Asia Pacific, Latin America, Africa

Country scope

U.S. States, U.S. Territories, Continental EU, Caribbean EU, Singapore, Vietnam, Indonesia, Brazil, Colombia

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global zika virus Testing market report based on test type and region:

  • Test Type Outlook (Revenue, USD Million, 2016 - 2027)

    • Nucleic Acid Amplification Testing (NAAT)

    • Serological Testing

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • U.S. States & Territories

      • U.S. States

      • U.S. Territories

    • Europe

      • Continental Europe

      • Caribbean Europe

    • Asia Pacific

      • Singapore

      • Vietnam

      • Indonesia

    • Latin America

      • Brazil

      • Colombia

    • Africa

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.